Human Astrocyte Population for Reliable Serum-Free Senescence Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to reliably induce senescent human astrocytes from astrocyte progenitor cells derived from human iPS cells, and there is uncertainty regarding the senescence and neurotoxic properties of differentiated astrocytes, particularly when cultured under serum-free conditions.
Innovation Solution
A method involving the proliferation and differentiation of astrocyte progenitor cells derived from human iPS cells under specific conditions, including a serum-free medium, to induce a human astrocyte population with defined senescence markers such as CDKN2A, IGFBP5, NNMT, HLA-DRB1, and HLA-DRB5, and controlled expression levels of C3, using factors like BMP4 and CNTF, to achieve a senescent astrocyte population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If astrocytes are completely differentiated and cultured for a long period to reproduce senescence, then senescent astrocytes can be obtained, but it is unclear whether or not senescent astrocytes can be obtained and the method is unreliable
Solution Approach 1:
The patent applies preliminary action by inducing astrocyte differentiation before the senescence reproduction step. Specifically, astrocyte progenitor cells are first differentiated into astrocytes using a differentiation medium containing BMP4 and CNTF, and only after this preliminary differentiation is complete is the senescence reproduction process initiated. This sequential approach ensures that the cells are in the appropriate developmental state before senescence is reproduced, thereby improving reliability while controlling the total culture time.
2Productivity
If astrocytes are exposed to serum in culture medium, then cell growth is supported, but irreversible activation occurs and the blood-brain barrier condition is not maintained
Solution Approach 1:
The patent applies parameter changes by modifying the culture medium composition to eliminate serum while maintaining appropriate growth conditions. The invention uses a serum-free culture medium supplemented with specific growth factors (BMP4 and CNTF) and other defined components that provide the necessary nutrients and signaling molecules without the harmful effects of serum. This parameter change in medium composition allows cell growth to be supported while avoiding irreversible activation and maintaining the blood-brain barrier condition.
3Object-affected harmful factors
If astrocytes are cultured under serum-free conditions to maintain blood-brain barrier condition, then in vivo-like environment is achieved, but differentiation into neurons and oligodendrocytes occurs and senescence status is unclear
Solution Approach 1:
The patent applies the intermediary principle by using specific growth factors (BMP4 and CNTF) as mediators to guide astrocyte differentiation and maintain purity under serum-free conditions. These growth factors act as intermediaries that provide directed differentiation signals, preventing spontaneous differentiation into neurons and oligodendrocytes while maintaining the astrocyte phenotype. The growth factors mediate the interaction between the serum-free medium and the astrocyte cells, ensuring both blood-brain barrier condition maintenance and differentiation purity.
Data Source
AI summary
An object of the present invention is to provide a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, a manufacturing method for the human astrocyte cell population; and an evaluation method for a test substance using the human astrocyte cell population. According to the present invention, there is provided a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, the human astrocyte cell population including at least 90% of human astrocytes, in which in the human astrocytes, a) CDKN2A is positive, b) at least one gene marker selected from the group consisting of IGFBP5, NNMT, HLA-DRB1, and HLA-DRB5 is positive, and c) an expression level of C3, which is standardized with GAPDH of a reference gene, is 0.05 copies/copies or less.